Dying mammalian cells emit numerous signals that interact with the host to dictate the
immunological correlates of cellular stress and death. In the absence of reactive antigenic …

In recent years, neutrophils have attracted increasing attention because of their cancer-
promoting effects. An elevated neutrophil-to-lymphocyte ratio is considered a prognostic …

The progression of cancer involves a critical step in which malignant cells escape from
control by the immune system. Antineoplastic agents are particularly efficient when they …

Dendritic cells (DC) are key sentinels of the host immune response with an important role in
linking innate and adaptive immunity and maintaining tolerance. There is increasing …

We developed a phenotypic screening platform for the functional exploration of dendritic
cells (DC). Here, we report a genome-wide CRISPR screen that revealed BCL2 as an …

Accumulating evidence indicates that Toll-like receptor (TLR) agonists proficiently (re)
instore cancer immunosurveillance as immunological adjuvants. So far, three TLR agonists …

Immunogenic cell death (ICD), which results from insufficient cellular adaptation to specific
stressors, occupies a central position in the development of novel anticancer treatments …

Background Prostate cancer (PC) responds to androgen deprivation therapy (ADT) usually
in a transient fashion, progressing from hormone-sensitive PC (HSPC) to castration-resistant …

The search for immunostimulatory drugs applicable to cancer immunotherapy may profit
from target‐agnostic methods in which agents are screened for their functional impact on …

BCL2 is an apoptosis-inhibitory oncoprotein that also possesses apoptosis-unrelated
activities. Pharmacological BCL2 inhibitors have been developed with the scope of driving …